10 results on '"C, Rouillac-Le Sciellour"'
Search Results
2. [Does the prevalence of recurrent pathogenic microdeletions and microdoublements in prenatal diagnosis lead to a reassessment of the evolution of non-invasive screening techniques? The example of region 22q11.2]
- Author
-
F, Vialard, C, Rouillac-Le Sciellour, J, Besseau-Ayasse, C, Oheix, B, Hervé, and D, Molina-Gomes
- Subjects
Heart Defects, Congenital ,Phenotype ,Pregnancy ,Chromosomes, Human, Pair 22 ,Prenatal Diagnosis ,DiGeorge Syndrome ,Prevalence ,Humans ,Female ,Chromosome Deletion ,Gene Deletion ,In Situ Hybridization, Fluorescence - Published
- 2016
3. Génotypage RhD fœtal non invasif sur sang maternel : vers une utilisation chez toutes les femmes enceintes RhD négatif
- Author
-
A. Cortey, Y. Brossard, C. Rouillac-Le Sciellour, and Bruno Carbonne
- Subjects
Gynecology ,medicine.medical_specialty ,Reproductive Medicine ,business.industry ,Non invasive ,RhD positive ,Obstetrics and Gynecology ,Medicine ,General Medicine ,business ,Genotyping - Abstract
Non invasive fetal RhD genotyping, based on polymerase-chain-reaction (PCR), is an accurate and validated technique. It allows a reduction by one-third of anti-D immunoglobulin injections to prevent RhD allo-immunization. In case of maternal anti-D immunization, fetal RhD genotyping allows to focus on RhD positive fetuses only the biologic and sonographic follow-up. The wide use of this technique implies the validation and economic evaluation of a commercial RhD genotyping kit, ready for use in non specialized laboratories.
- Published
- 2008
- Full Text
- View/download PDF
4. Noninvasive fetal RHD genotyping from maternal plasma
- Author
-
C. Rouillac-Le Sciellour, Yves Colin, C. Le Van Kim, Y. Brossard, J.-P. Cartron, Y. Guidicelli, Valérie Serazin, O. Oudin, and M. Menu
- Subjects
Fetus ,biology ,Biochemistry (medical) ,Clinical Biochemistry ,Hematology ,medicine.disease ,law.invention ,Andrology ,chemistry.chemical_compound ,chemistry ,Blood product ,law ,Genotype ,Hemolytic disease of the newborn (ABO) ,Immunology ,medicine ,SYBR Green I ,biology.protein ,Antibody ,Genotyping ,Polymerase chain reaction - Abstract
Fetal RHD genotyping from maternal plasma was performed by real-time PCR amplification of exons 7 and 10 of the RHD gene and the amplified products were detected either with SYBR Green I dye according to our previously published method [Mol Diagn 8 (2004) 23-31] or with hydrolysis probes in a new Free DNA Fetal Kit RhD((R)). Plasma specimen from 300 RhD-negative pregnant women (between 10 to 34 weeks of gestation) were analysed and validation of the results was ascertained either by RHD genotyping on amniotic cells or by blood typing of the neonate at birth. We found 100% concordant results when comparing the two methods. Two false-positive but no false-negative results were found. Thus, the sensitivity of the assay was 100% and the specificity superior than 99%. These data confirm the accuracy of fetal RHD genotyping on maternal plasma using the Free DNA Fetal Kit RhD, thus allowing to propose non invasive PCR-based fetal RHD genotyping for all RhD-negative pregnant women and to restrict the use of anti-D immunoglobulins only to those bearing an RhD-positive fetus.
- Published
- 2007
- Full Text
- View/download PDF
5. Paternité tardive : aspects spermatiques et génétiques
- Author
-
M. Dakouane-Giudicelli, François Vialard, Jacqueline Selva, N. Ledee, Yves Giudicelli, Valérie Serazin, C. Rouillac-Le Sciellour, M. Bergere, Olivier Cussenot, and Martine Albert
- Subjects
medicine.medical_specialty ,Spermiogenesis ,Obstetrics and Gynecology ,Physiology ,Aneuploidy ,Semen ,General Medicine ,Testicle ,Biology ,Sertoli cell ,medicine.disease ,Sperm ,medicine.anatomical_structure ,Endocrinology ,Reproductive Medicine ,Internal medicine ,medicine ,Achondroplasia ,Spermatogenesis - Abstract
The effect of maternal age on the risk of meiotic abnormality is well documented. In contrast little is known about the effect of the paternal age. The question of the risk related to paternal age is raised because of the increased demand of Assisted Reproduction Techniques for older men. This review focuses on the alterations of male semen parameters, testis histology and genetic risks related to age. The motility, vitality and morphology of spermatozoa and semen volume are found decreasing with age. Histomorphometric studies reveal various alterations including a thickening of the basal membrane when spermatogenesis is arrested. The number of germinal and Sertoli cells decreases with increased age. Up to 95 years old, we could find subjects with complete spermatogenesis. Chromosomal analyses in different studies have provided controversial results. Our investigation on subjects aged from 29 to 102 showed that the rate of aneuploidy in the group of aged subjects with preserved spermatogenesis was not statistically different from the young control group. However the incidence of postmeiotic aneuploidy was increased when spermiogenesis had stopped. On the other hand from epidemiological studies, autosomal dominant diseases are known to be associated with paternal age. However, in the case of achondroplasia and Apert syndrome, direct DNA sperm analysis did not reveal significant increase in the mutation frequency with paternal age.
- Published
- 2006
- Full Text
- View/download PDF
6. [Non invasive fetal RhD genotyping using maternal blood: time for use in all RhD negative pregnant women]
- Author
-
B, Carbonne, A, Cortey, C, Rouillac-Le Sciellour, and Y, Brossard
- Subjects
Fetal Diseases ,Rh-Hr Blood-Group System ,Genotype ,Pregnancy ,Prenatal Diagnosis ,Humans ,Female ,Maternal-Fetal Exchange ,Polymerase Chain Reaction - Abstract
Non invasive fetal RhD genotyping, based on polymerase-chain-reaction (PCR), is an accurate and validated technique. It allows a reduction by one-third of anti-D immunoglobulin injections to prevent RhD allo-immunization. In case of maternal anti-D immunization, fetal RhD genotyping allows to focus on RhD positive fetuses only the biologic and sonographic follow-up. The wide use of this technique implies the validation and economic evaluation of a commercial RhD genotyping kit, ready for use in non specialized laboratories.
- Published
- 2007
7. [Late paternity: spermatogenetic aspects]
- Author
-
M, Dakouane-Giudicelli, M, Bergère, M, Albert, V, Sérazin, C, Rouillac-Le Sciellour, F, Vialard, N, Lédée, O, Cussenot, Y, Giudicelli, and J, Selva
- Subjects
Adult ,Aged, 80 and over ,Chromosome Aberrations ,Male ,Mutation ,Humans ,DNA ,Middle Aged ,Aneuploidy ,Spermatogenesis ,Spermatozoa ,Paternal Age ,Aged - Abstract
The effect of maternal age on the risk of meiotic abnormality is well documented. In contrast little is known about the effect of the paternal age. The question of the risk related to paternal age is raised because of the increased demand of Assisted Reproduction Techniques for older men. This review focuses on the alterations of male semen parameters, testis histology and genetic risks related to age. The motility, vitality and morphology of spermatozoa and semen volume are found decreasing with age. Histomorphometric studies reveal various alterations including a thickening of the basal membrane when spermatogenesis is arrested. The number of germinal and Sertoli cells decreases with increased age. Up to 95 years old, we could find subjects with complete spermatogenesis. Chromosomal analyses in different studies have provided controversial results. Our investigation on subjects aged from 29 to 102 showed that the rate of aneuploidy in the group of aged subjects with preserved spermatogenesis was not statistically different from the young control group. However the incidence of postmeiotic aneuploidy was increased when spermiogenesis had stopped. On the other hand from epidemiological studies, autosomal dominant diseases are known to be associated with paternal age. However, in the case of achondroplasia and Apert syndrome, direct DNA sperm analysis did not reveal significant increase in the mutation frequency with paternal age.
- Published
- 2006
8. [Development of digital PCR molecular tests for clinical practice: principles, practical implementation and recommendations].
- Author
-
Denis JA, Nectoux J, Lamy PJ, Rouillac Le Sciellour C, Guermouche H, Alary AS, Kosmider O, Sarafan-Vasseur N, Jovelet C, Busser B, Nizard P, Taly V, and Fina F
- Subjects
- Clinical Laboratory Techniques standards, Female, Humans, Molecular Diagnostic Techniques standards, Polymerase Chain Reaction standards, Practice Guidelines as Topic, Pregnancy, Prenatal Diagnosis methods, Prenatal Diagnosis standards, Real-Time Polymerase Chain Reaction, Signal Processing, Computer-Assisted, Clinical Laboratory Techniques methods, Molecular Diagnostic Techniques methods, Polymerase Chain Reaction methods
- Abstract
Digital PCR (dPCR) is a 3rd generation technology that complements traditional end-point PCR and real-time PCR. It was developed to overcome certain limitations of conventional amplification techniques, in particular for the detection of small amounts of nucleic acids and/or rare variants. This technology is in a full swing because of its high sensitivity and major applications in various domains such as oncology, transplantation or non-invasive prenatal testing. Consequently, PCRd also has great interest in many areas of medical biology, particularly for clinical applications aiming at detecting and quantifying specific genetic or epigenetic alterations of nucleic acids, even with specimens containing very low concentration of the nucleic acids of interest (e.g. liquid biopsies). However, this technique requires a good training of users and compliance with certain precautions. A lack in such a knowledge can lead to many errors in the conduct of the experiment and the interpretation of the results. In this review, we present the context in which this technology has emerged by describing in particular its principle and the main factors that can influence the quality of the analysis. Then, we propose a number of practical recommendations for the implementation of a test based on dPCR in clinical laboratories with an eye on quality requirements.
- Published
- 2018
- Full Text
- View/download PDF
9. Could Digital PCR Be an Alternative as a Non-Invasive Prenatal Test for Trisomy 21: A Proof of Concept Study.
- Author
-
El Khattabi LA, Rouillac-Le Sciellour C, Le Tessier D, Luscan A, Coustier A, Porcher R, Bhouri R, Nectoux J, Sérazin V, Quibel T, Mandelbrot L, Tsatsaris V, Vialard F, and Dupont JM
- Subjects
- Chromosomes, Human, Pair 21 genetics, DNA blood, DNA Probes metabolism, Down Syndrome blood, Down Syndrome genetics, Humans, ROC Curve, Reproducibility of Results, Down Syndrome diagnosis, Multiplex Polymerase Chain Reaction methods, Prenatal Diagnosis methods
- Abstract
Objective: NIPT for fetal aneuploidy by digital PCR has been hampered by the large number of PCR reactions needed to meet statistical requirements, preventing clinical application. Here, we designed an octoplex droplet digital PCR (ddPCR) assay which allows increasing the number of available targets and thus overcomes statistical obstacles., Method: After technical optimization of the multiplex PCR on mixtures of trisomic and euploid DNA, we performed a validation study on samples of plasma DNA from 213 pregnant women. Molecular counting of circulating cell-free DNA was performed using a mix of hydrolysis probes targeting chromosome 21 and a reference chromosome., Results: The results of our validation experiments showed that ddPCR detected trisomy 21 even when the sample's trisomic DNA content is as low as 5%. In a validation study of plasma samples from 213 pregnant women, ddPCR discriminated clearly between the trisomy 21 and the euploidy groups., Conclusion: Our results demonstrate that digital PCR can meet the requirements for non-invasive prenatal testing of trisomy 21. This approach is technically simple, relatively cheap, easy to implement in a diagnostic setting and compatible with ethical concerns regarding access to nucleotide sequence information. These advantages make it a potential technique of choice for population-wide screening for trisomy 21 in pregnant women.
- Published
- 2016
- Full Text
- View/download PDF
10. Large-scale pre-diagnosis study of fetal RHD genotyping by PCR on plasma DNA from RhD-negative pregnant women.
- Author
-
Rouillac-Le Sciellour C, Puillandre P, Gillot R, Baulard C, Métral S, Le Van Kim C, Cartron JP, Colin Y, and Brossard Y
- Subjects
- Base Sequence, Diagnostic Errors, Erythroblastosis, Fetal blood, Erythroblastosis, Fetal diagnosis, Erythroblastosis, Fetal genetics, Exons, Female, Genotype, Humans, Infant, Newborn, Introns, Male, Polymerase Chain Reaction, Pregnancy, Prenatal Diagnosis, DNA blood, DNA genetics, Fetal Blood immunology, Rh-Hr Blood-Group System genetics
- Abstract
Background: The routine prenatal determination of fetal RhD blood group would be very useful in the management of pregnancies in RhD-negative women, as up to 40% of these pregnancies bear a RhD-negative fetus. The fetal DNA present in maternal plasma offers an opportunity for risk-free prenatal diagnosis., Aim: This study focused on the feasibility and accuracy of large-scale RhD fetal diagnosis in non-immunized and anti-D immunized RhD-negative women., Methods: Plasma DNA was extracted from 893 RhD-negative pregnant women and amplified in exons 7 and 10 of the RHD gene using conventional and real-time PCR. The results were then compared with the RHD fetal genotype determined on amniotic cells and/or the RhD phenotype of the red blood cells of the infants at birth., Results: After exclusion of 42 samples from women exhibiting a nonfunctional or rearranged RHD gene, fetal RhD status was predicted with a 99.5% accuracy. A strategy is also proposed to avoid the small number of false-positive and -negative results., Conclusion: Fetal RHD genotyping from maternal plasma DNA in different clinical situations may be used with confidence.
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.